Phase 4CompletedINTERVENTIONAL
Impact of Liraglutide 3.0 on Body Fat Distribution
ClinicalTrials.gov · NCT03038620 · Registry updated: 2021-11-19
- Condition / research focus
- Obesity, Visceral; Cardiovascular Diseases; Fat Disorder
- Sponsor
- University of Texas Southwestern Medical Center
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2017-01. Completion: 2020-10-13 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Liraglutide (drug) — also listed as: Saxenda
- Placebo (drug) — also listed as: Saline injection
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- University of Texas Southwestern Medical Center
Dallas, Texas, United States